Compare

Madrigal Pharmaceuticals, Inc. vs ANI Pharmaceuticals Inc vs Prestige Consumer Healthcare Inc. vs Corcept Therapeutics Inc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearMadrigal Pharmaceuticals, Inc.
MDGL
ANI Pharmaceuticals Inc
ANIP
Prestige Consumer Healthcare Inc.
PBH
Corcept Therapeutics Inc
CORT
Year ended2025-12-312025-12-312026-03-312025-12-31
Revenue$958.40M$883.37M$1.09B$761.41M
Revenue growth (YoY)+432.1%+43.8%-4.3%+12.8%
Gross marginn/an/a54.7%n/a
Operating margin-31.3%12.6%28.4%5.9%
Net margin-30.1%8.9%17.5%13.1%
Net income-$288.28M$78.34M$190.30M$99.65M
EPS (Diluted)-$12.85$3.32$3.91$0.82
Operating cash flow-$189.55M$185.22M$257.63M$142.00M
Free cash flow-$190.02M$171.39M$246.45M$141.78M
Cash & equivalents$198.69M$285.58M$63.87M$120.50M
Total assets$1.26B$1.44B$3.49B$836.65M
Total liabilities$656.90M$899.65M$1.61B$188.85M
Shareholders' equity$602.69M$540.72M$1.89B$647.80M
Return on year-end equity-47.8%14.5%10.1%15.4%
Shares outstanding22.84M22.49Mn/a105.97M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearMadrigal Pharmaceuticals, Inc.ANI Pharmaceuticals IncPrestige Consumer Healthcare Inc.Corcept Therapeutics Inc
Latest$958.40M
Ended 2025-12-31
$883.37M
Ended 2025-12-31
$1.09B
Ended 2026-03-31
$761.41M
Ended 2025-12-31
1 year earlier$180.13M
Ended 2024-12-31
$614.38M
Ended 2024-12-31
$1.14B
Ended 2025-03-31
$675.04M
Ended 2024-12-31
2 years earlier$0
Ended 2023-12-31
$486.82M
Ended 2023-12-31
$1.13B
Ended 2024-03-31
$482.38M
Ended 2023-12-31
3 years earlier$0
Ended 2022-12-31
$316.38M
Ended 2022-12-31
$1.13B
Ended 2023-03-31
$401.86M
Ended 2022-12-31
4 years earlier$0
Ended 2021-12-31
$216.14M
Ended 2021-12-31
$1.09B
Ended 2022-03-31
$365.98M
Ended 2021-12-31